Navigation Links
Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
Date:2/4/2008

BASEL, Switzerland, February 4 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Philippe Lutz MA Finance, as the company's first chief financial officer, effective immediately. He will be based at Synosia's new headquarters in Basel, Switzerland.

Lutz joins Synosia from Credit Suisse Investment Banking where he most recently served as a vice president of the global markets solutions group. In a nine-year career at Credit Suisse, he contributed to a broad range of capital market transactions and successfully completed the chartered financial analyst exams (CFA). Lutz is a Swiss national and earned his masters in business administration from the University of St. Gallen.

"Since Synosia started operations just over two years ago, we've established partnerships with Roche, Novartis and Syngenta, designed and completed our first clinical trial, prepared to start four phase II trials later this year, and built strong teams in both San Francisco and Basel," said the company's Chief Executive Officer and President Ian Massey.

"The establishment of our corporate headquarters in Switzerland and the appointment of Philippe Lutz is a further step in our progression to a mature development organization; it also underscores the importance of Switzerland as a centre of excellence for the management, clinical development and extension of our portfolio of compounds," Dr Massey continued.

"I knew that Synosia was the company I wanted to join once I met the management team and saw the extraordinary progress the company has made," said Lutz. "I was also pleased to learn of the new headquarters in Switzerland. The strength of Switzerland's pharmaceutical sector should help sustain Synosia's ambitious development programme."

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's corporate headquarters is in Basel, Switzerland.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact:

Synosia Therapeutics

In Europe:

Julie Walters at Tudor Reilly

Tel: +44(0)20-7016-7714

Mobile +44(0)775-3626967

julie.walters@tudor-reilly.com

In US:

Michele Parisi at Tudor Reilly

Tel: +1-925-864-5028

michele.parisi@tudor-reilly.com


'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
2. Synosia Therapeutics Announces Appointment of Chief Business Officer
3. Taligen Therapeutics Secures Series B Financing
4. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
6. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
9. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
11. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):